StoxBio Medica Laboratories Limited
NSE: BMLL · Unclassified
Ask the data
Instant answers about Bio Medica Laboratories Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 43.1 |
| EBITDA | 19.6 |
| Operating margin | 45.6% |
| Interest | 2.3 |
| Depreciation | 1.2 |
| Profit before tax | 16.2 |
| Tax | 4.4 |
| Net profit | 11.8 |
| EPS ₹ | 12.95 |
| Operating cash flow | -6.0 |
| Capex | 2.8 |
| Dividend paid | 0.0 |
| Total assets | 73.3 |
| Equity | 26.5 |
Half-yearly performance
last 2 half years · ₹ crore| H1 FY26* | H2 FY26 | |
|---|---|---|
| Revenue | 0.0 | 43.1 |
| Operating profit | 0.0 | 19.6 |
| Operating margin | — | 45.6% |
| Other income | 0.0 | 0.0 |
| Interest | 0.0 | 2.3 |
| Depreciation | 0.0 | 1.2 |
| Profit before tax | 0.0 | 16.2 |
| Tax | 0.0 | 4.4 |
| Net profit | 0.0 | 11.8 |
| EPS ₹ | 0.00 | 12.95 |
Returns & margins
trailing-twelve-month, per half year| H2 FY26 | |
|---|---|
| ROE | 44.4% |
| ROCE | 27.8% |
| Net margin | 27.3% |
| EBITDA margin | 45.6% |
| Debt / equity | 1.51 |
| Interest coverage | 8.19 |
| Asset turnover | 0.59 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '26 | |
|---|---|
| Share capital | 9.2 |
| Other equity / reserves | 17.3 |
| Total equity | 26.5 |
| Borrowings | 40.0 |
| Current liabilities | 19.2 |
| Non-current liabilities | 33.8 |
| Total assets | 73.3 |
| Property, plant & equipment | 10.3 |
| Investments | 0.0 |
| Inventories | 36.4 |
| Receivables | 10.8 |
| Cash & equivalents | 0.1 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | -6.0 |
| Cash from investing | -2.1 |
| Cash from financing | 8.2 |
| Capex | 2.8 |
| Free cash flow | -8.8 |
| Dividends paid | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Bio Medica Laboratories Limited | 133 | 145.35 | 11.3 | 5.03 | 44.4% |
StoxGud checklist: Bearish setup · 3/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Bio Medica Laboratories Limited?
Bio Medica Laboratories Limited (BMLL) closed at ₹145.35 on NSE on 06 Nov 2026.
What is the market cap of Bio Medica Laboratories Limited?
₹133 crore at the latest close.
What is the P/E ratio of Bio Medica Laboratories Limited?
11.3, on trailing-twelve-month earnings from its filings.
How fast is Bio Medica Laboratories Limited growing?
Not enough filed history yet to measure Bio Medica Laboratories Limited's growth.
How profitable is Bio Medica Laboratories Limited?
On a trailing-twelve-month basis return on equity is 44.4%, return on capital employed 27.8%, operating margin 45.6%, net margin 27.3%.
How much debt does Bio Medica Laboratories Limited have?
Bio Medica Laboratories Limited is highly geared: debt to equity is 1.51 with borrowings of ₹40 cr against cash of ₹0 cr (balance sheet of 2026-03-31). Operating profit covers interest 8.2 times.
Financials parsed from Bio Medica Laboratories Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Half-yearly from H1 FY26, annual from FY26, balance sheet from Mar '26. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.